224 related articles for article (PubMed ID: 1315865)
21. Coupling of H(+)-K(+)-ATPase activity and glucose oxidation in gastric glands.
Fryklund J; Gedda K; Scott D; Sachs G; Wallmark B
Am J Physiol; 1990 May; 258(5 Pt 1):G719-27. PubMed ID: 2159239
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo.
Shin JM; Homerin M; Domagala F; Ficheux H; Sachs G
Biochem Pharmacol; 2006 Mar; 71(6):837-49. PubMed ID: 16405921
[TBL] [Abstract][Full Text] [Related]
23. [Protective effect of proton pump inhibitor on the gastric mucosa].
Kawano S; Tsuji S; Masuda E; Hayashi N; Tsujii M; Michida T; Kobayashi I; Fusamoto H; Kamada T
Nihon Rinsho; 1992 Jan; 50(1):33-8. PubMed ID: 1311787
[TBL] [Abstract][Full Text] [Related]
24. Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs.
Nagaya H; Inatomi N; Satoh H
Jpn J Pharmacol; 1991 Apr; 55(4):425-36. PubMed ID: 1886288
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of the gastric (H+ + K+)-ATPase by fenoctimine.
Reenstra WW; Shortridge B; Forte JG
Biochem Pharmacol; 1985 Jul; 34(13):2331-4. PubMed ID: 2990481
[TBL] [Abstract][Full Text] [Related]
26. Effect of carbachol or histamine stimulation on rat gastric membranes enriched in (H+-K+)-ATPase.
Im WB; Blakeman DP; Fieldhouse JM; Rabon EC
Biochim Biophys Acta; 1984 May; 772(2):167-75. PubMed ID: 6326823
[TBL] [Abstract][Full Text] [Related]
27. A newly synthesized pyridine derivative, (Z)-5-methyl-2-[2-(1-naphthyl)ethenyl]-4-piperidinopyridine hydrochloride (AU-1421), as a reversible gastric proton pump inhibitor.
Hioki Y; Takada J; Hidaka Y; Takeshita H; Hosoi M; Yano M
Arch Int Pharmacodyn Ther; 1990; 305():32-44. PubMed ID: 2173509
[TBL] [Abstract][Full Text] [Related]
28. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione.
Fujisaki H; Shibata H; Oketani K; Murakami M; Fujimoto M; Wakabayashi T; Yamatsu I; Yamaguchi M; Sakai H; Takeguchi N
Biochem Pharmacol; 1991 Jul; 42(2):321-8. PubMed ID: 1650210
[TBL] [Abstract][Full Text] [Related]
29. Irreversible inactivation of rat gastric (H+-K+)-ATPase in vivo by omeprazole.
Im WB; Blakeman DP; Davis JP
Biochem Biophys Res Commun; 1985 Jan; 126(1):78-82. PubMed ID: 2982382
[TBL] [Abstract][Full Text] [Related]
30. Biochemical and pharmacological characteristics of 3-butyryl-8-methoxy-4-[(2-thiophenyl)amino]quinoline, a new proton-pump inhibitor, in rabbit gastric microsomes and in rats.
Kim KB; Chang MS; Chung YK; Sohn SK; Kim SG; Choi WS
J Pharm Pharmacol; 1998 May; 50(5):521-9. PubMed ID: 9643446
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of gastric H+,K(+)-ATPase by the anti-ulcer agent, sofalcone.
Murakami S; Muramatsu M; Aihara H; Otomo S
Biochem Pharmacol; 1991 Sep; 42(7):1447-51. PubMed ID: 1656986
[TBL] [Abstract][Full Text] [Related]
32. Gastric antisecretory properties of SCH 32651.
Chiu PJ; Barnett A; Tetzloff G; Kaminski J
Arch Int Pharmacodyn Ther; 1984 Jul; 270(1):116-27. PubMed ID: 6238577
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of gastric H+, K+ adenosine triphosphatase (ATPase) by substituted naphthylalkylimidazoles.
Serrato C; Waterbury D; Loury D; Smith W
Proc West Pharmacol Soc; 1989; 32():249-53. PubMed ID: 2550945
[No Abstract] [Full Text] [Related]
34. BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions.
Kromer W; Postius S; Riedel R; Simon WA; Hanauer G; Brand U; Gönne S; Parsons ME
J Pharmacol Exp Ther; 1990 Jul; 254(1):129-35. PubMed ID: 2164086
[TBL] [Abstract][Full Text] [Related]
35. [Studies on the intracellular pharmacodynamic properties of proton pump inhibitors and the inhibitory mechanism of acid secretion].
Saito E; Matsuo Y
Nihon Rinsho; 1992 Jan; 50(1):18-25. PubMed ID: 1311783
[TBL] [Abstract][Full Text] [Related]
36. SCH 28080 is a lumenally acting, K+-site inhibitor of the gastric (H+ + K+)-ATPase.
Keeling DJ; Laing SM; Senn-Bilfinger J
Biochem Pharmacol; 1988 Jun; 37(11):2231-6. PubMed ID: 2837231
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of the K+-competitive H+,K+-ATPase inhibitor AZD0865 in isolated rat gastric glands.
Kirchhoff P; Andersson K; Socrates T; Sidani S; Kosiek O; Geibel JP
Am J Physiol Gastrointest Liver Physiol; 2006 Nov; 291(5):G838-43. PubMed ID: 16798725
[TBL] [Abstract][Full Text] [Related]
38. Properties of the reversible, K(+)-competitive inhibitor of the gastric (H+/K+)-ATPase, SK&F 97574. II. Pharmacological properties.
Parsons ME; Rushant B; Rasmussen TC; Leach C; Ife RJ; Postius S; Pope AJ
Biochem Pharmacol; 1995 Nov; 50(10):1551-6. PubMed ID: 7503756
[TBL] [Abstract][Full Text] [Related]
39. Effect of inhibition of pentagastrin-stimulated acid secretion on gastric mucosal gland luminal pressure.
Synnerstad I; Persson AE; Holm L
Acta Physiol Scand; 1997 May; 160(1):103-11. PubMed ID: 9179318
[TBL] [Abstract][Full Text] [Related]
40. The relationship between gastric acid secretion and gastric H+,K+-ATPase activity.
Wallmark B; Larsson H; Humble L
J Biol Chem; 1985 Nov; 260(25):13681-4. PubMed ID: 2997178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
